영상 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커별, 영상 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Imaging Biomarkers Market Summary

The global imaging biomarkers market size was estimated at USD 13.95 billion in 2024 and is projected to reach USD 39.23 billion by 2033, growing at a CAGR of 12.62% from 2025 to 2033. The growth of the market can be attributed to the increasing burden of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions.

The need for precise, non-invasive diagnostic methods and early disease detection has elevated the clinical relevance of imaging biomarkers. Furthermore, the growing emphasis on precision medicine and patient stratification has reinforced their role in therapeutic decision-making and clinical trial design. Supportive regulatory developments from agencies such as the U.S. FDA and EMA, which are advancing qualification pathways for imaging biomarkers, are enhancing industry confidence. Concurrently, public-private investments in translational imaging research are strengthening discovery, validation, and standardization initiatives across academic and industrial settings.

The current market dynamics emphasize upon an active period of innovation and consolidation. In 2025, Roche was granted FDA approval over its Elecsys PRO-C3 test to measure liver fibrosis and Thermo Fisher Scientific and Roche Diagnostics enlarged their biomarker cancer portfolios with companion diagnostic assays. Such strategic takeovers like the one of Eurofins Scientific to acquire the diagnostic activities of Synlab in Spain show a sense of move towards a networked biomarker services. Thermo Fisher has collaborated with UK Biobank in partnerships with technology developers to undertake massive validation and data integration of biomarkers and bioinformatics.

The market still continues to be redefined by technological advancement. Novel hybrid imaging systems (PET/CT, PET/MRI), novel high-specificity radiotracers, and artificial intelligence and radiomics are allowing quantitative imaging biomarkers (QIBs), which compose objective, reproducible measurements of disease states. Harmonized imaging protocols and cloud-based analytics platforms are enhancing cross-site reproducibility, which is a requirement to qualify regulation and multicenter trials.

The imaging biomarkers industry is growing in recent years due to the essential advances in molecular diagnostics. Cizzle Biotech introduced CIZ1B biomarker assay in March 2025, which is a non-invasive blood test to detect lung cancer at its early stage. This assay can be used to complement imaging-based diagnostic tests like CT and PET scans by identifying high-risk patients, allowing them to be intervened earlier and enhancing their diagnostic processes. The partnership with iGenomeDX will provide scalable accessibility in the U.S., improving its accessibility and supporting the combination of molecular and imaging biomarkers.

In August 2024, Hitachi High-Tech collaborated with Gencurix to create digital technology-based cancer molecular diagnostic tests with biomarker discovery. This project aids personalized medicine by connecting the molecular knowledge to the imaging data to allow the creation of a more specific diagnosis and treatment plan. These two developments point to the trend of combining molecular and imaging biomarkers which is fueling the growth of the market by enhancing diagnostic accuracy, speeding up the process of drug development and by facilitating earlier detection of the disease. All these developments lend strength to the trends toward the use of a more combined biomarker approach, a trend that ongoing future development has put the market squarely on the road to innovation, clinical integration, and a long-term growth trajectory.

As the issue of reimbursement and standardization continues, the integration of imaging with data science and molecular diagnostics is making imaging biomarkers a key component of the diagnostics, drug development, and personalized therapy. Further investment on AI-based quantification as well as approved imaging outcomes will support sustainable market expansion during the forecast period.

Global Imaging Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global imaging biomarkers market report based on biomarkers, imaging technology,application, end use, and region.

• Biomarkers Outlook (Revenue, USD Billion, 2021 - 2033)
• Anatomical biomarkers
• Functional biomarkers
• Molecular/Nuclear Biomarkers
• Quantitative Imaging Biomarkers
• Others
• Imaging Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• MRI
• CT
• PET
• SPECT
• Ultrasound
• Others
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Diagnostic/imaging centers
• Pharmaceutical and Biotech Companies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Biomarkers
  • 1.2.2. Imaging Technology
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising demand for early diagnosis and personalized medicine
    • 3.2.1.2. Advancements in imaging and molecular biomarker technologies
    • 3.2.1.3. Regulatory approvals supporting clinical adoption
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of imaging equipment and diagnostic tests
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Imaging Biomarkers Market: Biomarkers Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Imaging Biomarkers Market Biomarkers Movement Analysis
• 4.3. Global Imaging Biomarkers Market Size & Trend Analysis, by Biomarkers, 2021 to 2033 (USD Million)
• 4.4. Anatomical Biomarkers
  • 4.4.1. Global Anatomical Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Functional Biomarkers
  • 4.5.1. Global Functional Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Molecular/Nuclear Biomarkers
  • 4.6.1. Global Molecular/Nuclear Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Quantitative Imaging Biomarkers
  • 4.7.1. Global Quantitative Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Imaging Biomarkers Market: Imaging Technology Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Imaging Biomarkers Market Imaging Technology, Movement Analysis
• 5.3. Global Imaging Biomarkers Market Size & Trend Analysis, by Imaging Technology, 2021 to 2033 (USD Million)
• 5.4. MRI
  • 5.4.1. Global MRI Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. CT
  • 5.5.1. Global CT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. PET
  • 5.6.1. Global PET Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. SPECT
  • 5.7.1. Global SPECT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Ultrasound
  • 5.8.1. Global Ultrasound Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Imaging Biomarkers Market: Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Imaging Biomarkers Market Application Movement Analysis
• 6.3. Global Imaging Biomarkers Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Diagnostics
  • 6.4.1. Global Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Drug Discovery & Development
  • 6.5.1. Global Drug Discovery & Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Personalized Medicine
  • 6.6.1. Global Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Disease Risk Assessment
  • 6.7.1. Global Disease Risk Assessment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Imaging Biomarkers Market: End Use Business Analysis

• 7.1. Segment Dashboard
• 7.2. Global Imaging Biomarkers Market End Use Movement Analysis
• 7.3. Global Imaging Biomarkers Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Global Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Diagnostic/imaging centers
  • 7.5.1. Global Diagnostic/imaging centers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Pharmaceutical and Biotech Companies
  • 7.6.1. Global Pharmaceutical and Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Imaging Biomarkers Market: Regional Estimates & Trend Analysis by Biomarkers, Imaging Technology, Application & End Use

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 8.3. North America
  • 8.3.1. North America Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Participant's Overview
  • 9.4.1. Siemens Healthineers
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Biomarkers Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. F. Hoffmann-La Roche AG
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Biomarkers Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Abbott Laboratories
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Biomarkers Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Thermo Fisher Scientific Inc.
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Biomarkers Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Siemens Healthineers AG
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Biomarkers Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. QIAGEN
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Biomarkers Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Bio-Rad Laboratories, Inc.
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Biomarkers Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. PerkinElmer Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Biomarkers Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Brainomix
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Biomarkers Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. IXICO plc
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Biomarkers Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Median Technologies
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Biomarkers Benchmarking
    • 9.4.11.4. Strategic Initiatives